Guirguis A

Pharmacy, Medical School, The Grove, Swansea University, Swansea, SA2 8PP, Wales, UK.

10 papers · ORCID

ArticleMDMA

Psychoactive Synthetic Adulterants in Tablets Sold as MDMA after the COVID-19 Pandemic: Implications for Central Effects.

De Luca MA, Miliano C, Roxburgh A +7

Europe PMC2026
ArticlePsychedelics

Focus on Cognitive Enhancement: A Narrative Overview of Nootropics and "Smart Drug" Use and Misuse.

Schifano F, Bonaccorso S, Arillotta D +4

Europe PMC2025
ArticleMDMA

Drugs Used in "Chemsex"/Sexualized Drug Behaviour-Overview of the Related Clinical Psychopharmacological Issues.

Schifano F, Bonaccorso S, Arillotta D +6

Europe PMC2025
ArticleKetamine

Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders: A pharmacovigilance perspective.

Chiappini S, Guirguis A, Schifano N +9

Europe PMC2025
ArticleKetamine

Stimulant and hallucinogenic novel psychoactive substances; an update.

Schifano F, Vento A, Scherbaum N +1

Europe PMC2023
ArticlePsychedelics

The Benzydamine Experience: A Systematic Review of Benzydamine Abuse.

Chiappini S, Miuli A, Mosca A +6

Europe PMC2021
ArticlePsychedelics

COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis.

Arillotta D, Guirguis A, Corkery JM +2

Europe PMC2021
ArticlePsychedelics

Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach.

Catalani V, Arillotta D, Corkery JM +3

Europe PMC2020
ArticlePsychedelics

Psychedelic Fauna for Psychonaut Hunters: A Mini-Review.

Orsolini L, Ciccarese M, Papanti D +4

Europe PMC2018
ArticlePsilocybin

The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.

Orsolini L, Papanti GD, De Berardis D +3

Europe PMC2017